Head-to-head · free
Tempus AI, Inc. vs TransMedics Group, Inc.
TEM vs TMDX — return on capital, cash generation, margins and balance sheet side by side.
TEM
3 / 9
measures where TEM leads
TMDX
6 / 9
measures where TMDX leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | TEM · FY2025 | TMDX · FY2025 |
|---|---|---|
| Revenue | $1.3B | $605.5M |
| Net income | (245.0M) | $190.3M |
| Revenue growth (yearly, multi-year) | 83.4% | 111.5% |
| Free cash flow | (239.1M) | $133.6M |
| Free cash flow margin | -18.8% | 22.1% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -89.5% | 54.2% |
| Gross margin | 62.7% | 59.9% |
| Operating margin | -19.9% | 17.9% |
| Net debt / EBITDA | -4.22x | 0.18x |
Figures are as reported by each company; latest fiscal year shown.
Where Tempus AI, Inc.'s cash went (FY2025)
- Capital spending
- $21.0M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where TransMedics Group, Inc.'s cash went (FY2025)
- Capital spending
- $59.3M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free